VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. - Wikidata - awgldk - TriplyDB

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial.

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial.

http://www.wikidata.org/entity/Q34138826

about

Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.Hodgkin lymphoma at the paediatric oncology unit of gabriel touré teaching hospital, bamako, mali: 5-year experience Relapse after treatment of pediatric Hodgkin lymphoma: outcome and role of surveillance after end of therapy.Paediatric radiotherapy in Australia and New Zealand: an anachronism in 2003?Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose.Outcome of a risk-related therapeutic strategy used prospectively in a population-based study of Hodgkin's lymphoma in adolescents.Pediatric Hodgkin lymphoma survivors at negligible risk for significant bone mineral density deficits.ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.The evolving role of radiation therapy in pediatric Hodgkin's disease.Hodgkin's lymphoma presenting with heart failure: a case report Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease ‐ a feasibility study.

P2860

Q34115831-6021E35E-ACB1-4817-AF1A-A6310DF60AAA Q34166545-B15C2092-1CC3-409A-ABCB-E9CBEB9BA95F Q34590943-7E4E78D8-B7C6-426C-9333-DA4E0EAD8588 Q35036383-B6799FDA-8538-46FE-A8B8-F40226F1CAB2 Q35594408-FF30AA0D-A19F-4EFB-A295-48703246B468 Q36099062-63C1EB93-19D1-4B44-85AE-9B97A3E785FE Q36309826-BFB52C93-3CCD-4EF2-9391-D1019DF67A02 Q36479283-92924C71-E99D-49C6-BAA8-27497E2E6644 Q36491663-B85B26D2-B9AC-46D6-87FE-97F9F831D432 Q36608682-A72C7589-44B3-4223-A3F7-75995621B622 Q37315290-1606C61B-B968-407B-AAA6-D2E9496F44D5 Q38195016-9A53DC15-A5CF-4200-AFBD-BD3CFFA91748 Q38396485-59CD1769-DC79-45F2-8104-E9741E998BF3 Q38684561-E3851AB7-C0B6-4EE2-8FA4-45C83CE55E0A Q38823537-D9F1F8D6-0897-46EA-A828-94366D0DD0B9 Q40364574-2A486255-8F16-452E-98CB-CD169FB70FFD Q44916266-437F1F49-73BE-440A-A69C-31AF9BAA6C7C Q53485702-A8794BD4-EF6D-4D99-AF3C-79C5E8199DB7 Q54995111-4DDD9D67-2CF1-4FCC-81BC-DDCB1D0913BA

P2860

VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial.

http://www.wikidata.org/entity/Q34138826

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@ast

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@en

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@nl

type

label

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@ast

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@en

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@nl

prefLabel

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@ast

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@en

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@nl

P1433

Q34138826-4B272423-EF9F-4CCE-ADB5-2B34E488FABB

P1476

Q34138826-ED26F078-8691-4AF2-8FB7-715E9A717F43

P2093

Q34138826-198348C7-61EB-4D2D-A8D6-F30B9D63B142

Q34138826-26CBC3E0-DD84-4608-A5C9-FD3F5CDD27F7

Q34138826-37984C97-BA30-420C-A1AD-847765FB33B6

Q34138826-3A23FA45-9E59-4B21-BB3B-21DF8BE418E9

Q34138826-603823D7-5464-4720-9161-6778D5B8717D

Q34138826-8EEC7BBE-122F-4705-95F3-03032EA9F70A

Q34138826-983EBE93-53DB-4510-80C0-965A0FD93EBA

Q34138826-BE736820-C603-462E-9FCA-3686F07AAA2A

Q34138826-D52CD558-BBA0-4A98-975E-3C02DD158A05

Q34138826-E5815AD3-EE15-448A-8D5A-8A0658DCD388

P304

Q34138826-323447C6-D27B-4398-9158-BE4A496B7ADC

P31

Q34138826-85C10DAD-DDE0-4947-A0FA-81A3B51B0B44

P356

Q34138826-CE730A93-0A6B-4F74-BCAF-119FB0D33103

P407

Q34138826-E6BD10E9-1F35-46F0-B676-BA24CD8E880F

P433

Q34138826-B0CB74D5-8826-489F-B65D-B8E20CFBF836

P478

Q34138826-7F4A68AB-7CC6-442D-B561-9F51B1C9BC0C

P577

Q34138826-A9EEF58E-8D22-41FF-9EFE-12B9B0D79FD0

P698

Q34138826-1F727A44-9B76-4A59-BF64-0C09E2FD77DF

P921

Q34138826-256DC4AE-4612-43BB-97ED-17C4F1720D00

P356

JCO.2002.12.101

P1433

Journal of Clinical Oncology

P1476

VAMP and low-dose, involved-fi ...... a prospective clinical trial.

@en

P2093

Amy Louise Billett

http://www.w3.org/2001/XMLSchema#string

Craig A Hurwitz

http://www.w3.org/2001/XMLSchema#string

Howard J Weinstein

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Young

http://www.w3.org/2001/XMLSchema#string

Karen C Marcus

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Larry Kun

http://www.w3.org/2001/XMLSchema#string

Melissa M Hudson

http://www.w3.org/2001/XMLSchema#string

Michael P Link

http://www.w3.org/2001/XMLSchema#string

Nancy J Tarbell

http://www.w3.org/2001/XMLSchema#string

P304

3081-3087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2002.12.101

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12118021

http://www.w3.org/2001/XMLSchema#string

P921